Sterling Capital Management’s C4 Therapeutics CCCC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$6.67K Sell
2,002
-41
-2% -$153 ﹤0.01% 2728
2026
Q2
$9.5K Buy
+2,043
New +$6.99K ﹤0.01% 2244
2025
Q2
– Sell
-1,081
Closed -$1.73K – 3286
2025
Q1
$1.73K Sell
1,081
-797
-42% -$2.38K ﹤0.01% 2645
2024
Q4
$6.76K Buy
1,878
+1,692
+910% +$8.41K ﹤0.01% 2324
2024
Q3
$1.06K Buy
+186
New +$1.12K ﹤0.01% 2491

Other funds holding CCCC

Sterling Capital Management's CCCC Position: Q3 2026 in Review

Sterling Capital Management reduced its C4 Therapeutics (CCCC) stake by 2% in Q3 2026, selling an estimated $153 and leaving 2,002 shares worth $6.67K. The position accounts for ﹤0.01% of the portfolio, ranked #2728.

Sterling Capital Management first reported a position in CCCC in Q3 2024 and has held it in 5 quarters since. The position peaked at $9.5K in Q2 2026. 152 funds tracked by Wall St. Rank hold CCCC as of Q3 2026.

  • Sterling Capital Management held 2,002 shares of C4 Therapeutics worth $6.67K as of Q3 2026.
  • Sterling Capital Management sold 41 C4 Therapeutics shares in Q3 2026, an estimated $153.
  • C4 Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #2728 holding.
  • Sterling Capital Management first reported a position in C4 Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • Sterling Capital Management's C4 Therapeutics position peaked at $9.5K in Q2 2026.
  • 152 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.